Autologous Bronchial Basal Cell Preparation for Lung Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung diseases such as COPD, bronchiectasis, and pulmonary fibrosis cannot effectively repair damaged lung structures, leading to progressive disease progression and limited therapeutic options.
Innovation Solution
Development of a clinical-grade autologous bronchial basal cell preparation process involving tissue biopsy, enzymolysis, plating, amplification culture, and formulation into a deliverable liquid, ensuring high purity and safety for transplantation to repair lung tissue and improve pulmonary function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment methods (LAMA, LABA+ICS, antibiotics) are used for lung diseases, then symptomatic relief is achieved, but the damaged lung structures cannot be repaired and disease progression continues
Solution Approach 1:
The patent uses autologous bronchial basal cells that are harvested from the patient's own lung tissue and cultured to expand the cell population. These self-derived cells are then retransplanted to repair damaged lung structures, eliminating the need for external donors and avoiding immune rejection while enabling structural regeneration that conventional medications cannot provide
Solution Approach 2:
The patent performs preliminary culturing and amplification of bronchial basal cells ex vivo before transplantation. This preliminary action allows the cells to proliferate and reach sufficient numbers for effective transplantation, ensuring that enough viable cells are available to repair the damaged lung structures when retransplanted
2Quantity of substance
If bronchial basal cells are cultured and amplified ex vivo for transplantation, then sufficient cell numbers are obtained for effective treatment, but the risk of contamination (bacteria, mycoplasma) increases during the culture process
Solution Approach 1:
The patent employs sterile culture conditions and maintains an aseptic environment throughout the ex vivo culturing and amplification process. This inert/sterile atmosphere prevents contamination by bacteria, mycoplasma, and other pathogens while allowing the bronchial basal cells to proliferate to sufficient numbers for transplantation
Solution Approach 2:
The patent uses sterile culture media and reagents as intermediaries to support cell growth without introducing contaminants. These carefully controlled cultural conditions enable cell amplification while acting as a barrier against harmful contaminants
3Reliability
If autologous cell transplantation is performed to repair lung structures, then immune rejection is avoided, but the complexity of the preparation process increases
Solution Approach 1:
The patent uses the patient's own bronchial basal cells for transplantation, making the cells inherently immune-compatible. This self-service approach eliminates the need for immunosuppressive drugs and avoids immune rejection, though it requires establishing a sterile culture system to amplify the cells before retransplantation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enables the production of sterile, mycoplasma-free bronchial basal cells that can differentiate into mature lung cells, effectively repairing lung tissue and improving pulmonary function in patients with lung diseases.
Implementation Method 1
enzymolysis: digesting the bronchoscopic brushed-off biopsy tissue, and collecting digested cells after terminating the digesting
Data Source
AI summary
Provided are a clinical-grade autologous bronchial basal cell, a deliverable formulation thereof, and a preparation process. The preparation process comprises the following steps: acquiring and digesting an in vitro active bronchoscopic brushed-off biopsy tissue, and collecting cells after digestion is terminated; plating the digested cells on a culture plate pre-coated with feeder layer cells, collecting the cultured cells to perform amplification culture on a culture plate pre-coated with feeder layer cells, and when the cells grow to cover 50%-90% of the surface area of the culture plate, performing cell passage operation; and when passaged culture cells grow to cover 85%-95% of the surface area of a culture dish, digesting and collecting adhered cells, and washing. The clinical-grade bronchial basal cell prepared by this method can differentiate stably after the cells reach the lesion and significantly achieve the damaged lung tissue regeneration.